Shots:
- SpringWorks to receive $35M as upfront and $ 375M as clinical, regulatory, and commercial milestones and is eligible to receive royalties on future net sales of PF-04457845. Jazz to get an exclusive license of all assets relating to the FAAH inhibitor program including PF-04457845
- The acquisition magnifies Jazz’s neuroscience pipeline into a new disease area, further optimizes SpringWorks’ strategic focus on targeted oncology
- Jazz will initially focus on developing PF-04457845 as a treatment in PTSD for patients with inadequate response to currently approved therapies
Click here to read full press release/ article | Ref: PRNewswire | Image: Spring Works
The post Jazz Pharmaceuticals Acquires SpringWorks’ FAAH Inhibitor Program for Post-Traumatic Stress Disorder first appeared on PharmaShots.
